Aripiprazole Once-Monthly vs Oral Antipsychotics for Schizophrenia

"The risk profile of Aripiprazole Once-Monthly is rated at 3, as this medication has received FDA approval and entered Phase 4 trials."

"The information on clinicaltrials.gov implies that this trial is no longer actively recruiting for participants, as the last update was made back in June of 2015; however, there are 388 other medical trials seeking volunteers at present."

"The age requirements for enrolment in this trial are 18 to 60. Meanwhile, there are 55 clinical trials that accept patients under the legal threshold and 199 studies open to elderly individuals above 65 years of age."

"This trial is recruiting two-hundred participants aged 18 to 60 with a current diagnosis of schizophrenia that has been present for at least six months. The inclusion criteria requires they are able to provide written informed consent, understand the nature and requirements of the study, read and comprehend text in order to complete assessments scales, have been prescribed a single oral antipsychotic medication for three months prior to screening, and comply with birth control regulations if applicable."

"Currently, 54 clinical trials examining Aripiprazole Once-Monthly are underway. Of these active studies, 15 have progressed to Phase 3. Toronto is the primary research locus for this particular treatment; however, there are 1271 other locations conducting investigations on its efficacy and safety."

"Aripiprazole Once-Monthly is commonly utilized to mitigate irritability. It can also be a viable treatment option for post traumatic stress disorder (PTSD), dementia, and Alzheimer's disease."

"Unfortunately, this clinical trial is not open to recruitment at the moment. The listing was first published on December 1st 2014 and last modified on June 3rd 2015. However, there are 334 trials actively looking for people with schizophrenia and 54 studies welcoming individuals taking Aripiprazole Once-Monthly as part of their treatment regimen."